menu
    • menu
    [{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Egetis Therapeutics \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Egetis Therapeutics \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Pharma Consulting Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Pharma Consulting Group","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Pharma Consulting Group"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"University of Edinburgh | NHS Lothian","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Undisclosed","graph2":"Phase I","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ University of Edinburgh | NHS Lothian","highestDevelopmentStatusID":"6","companyTruncated":"Egetis Therapeutics \/ University of Edinburgh | NHS Lothian"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Neurology","graph2":"Phase I","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egetis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Premier Research Group | Egetis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tiratricol","moa":"NR1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egetis Therapeutics \/ Premier Research Group | Egetis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Premier Research Group | Egetis Therapeutics"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"AnovoRx | Egetis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tiratricol","moa":"NR1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egetis Therapeutics \/ AnovoRx | Egetis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ AnovoRx | Egetis Therapeutics"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Tiratricol","moa":"Thyroid hormone receptor beta","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","highestDevelopmentStatusID":"8","companyTruncated":"Egetis Therapeutics \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"}]

    Find Clinical Drug Pipeline Developments & Deals by Egetis Therapeutics

    Menu

    Egetis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : AnovoRx | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

                            Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2023

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : AnovoRx | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Premier Research Group | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

                            Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2022

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2019

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 31, 2018

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2018

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : University of Edinburgh | NHS Lothian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PP100-01 (Calmangafodipir) for Overdose of Paracetamol

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2017

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : University of Edinburgh | NHS Lothian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triac Trial II in MCT8 Deficiency Patients

                            Details : Triac is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 24, 2015

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pharma Consulting Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2012

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pharma Consulting Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth